Lexicon Pharmaceuticals to Participate in the 39th Annual J.P. Morgan Healthcare Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that Lonnel Coats, the company’s CEO, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 2:50 p.m. ET. A webcast will be available on Lexicon’s website in the 'Events' section and will remain archived for two weeks. Lexicon is focused on pioneering medicines through its Genome5000™ program, targeting over 100 protein targets for therapeutic potential in various diseases. The company has a pipeline in neuropathic pain, heart failure, diabetes, and metabolism.
- None.
- None.
THE WOODLANDS, Texas, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon’s president and chief executive officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 2:50 p.m. ET.
A webcast of the event will be available in the “Events” section of the Lexicon website at www.lexpharma.com. An archived version of the webcast will be available on the website for two weeks.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, heart failure, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position, long-term outlook on its business and the clinical development and therapeutic and commercial potential of its drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of LX9211, sotagliflozin and its other potential drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
For Inquiries:
Chas Schultz
Executive Director, Corporate Communications and Investor Relations
Lexicon Pharmaceuticals
(281) 863-3421
cschultz@lexpharma.com
FAQ
When will Lexicon Pharmaceuticals present at the J.P. Morgan Healthcare Conference 2021?
How can I watch the Lexicon Pharmaceuticals presentation at the conference?
What is the focus of Lexicon Pharmaceuticals' drug development?
What is the significance of the Genome5000™ program for Lexicon Pharmaceuticals?
What are the key therapeutic areas Lexicon Pharmaceuticals is developing drugs for?
